Serum metabolomics reveals the metabolic profile and potential biomarkers of ankylosing spondylitis†

IF 3 4区生物学 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY

Molecular omics Pub Date : 2024-06-25 DOI:10.1039/D4MO00076E

Liuyan Li, Shuqin Ding, Weibiao Wang, Lingling Yang, Gidion Wilson, Yuping Sa, Yue Zhang, Jianyu Chen and Xueqin Ma

{"title":"Serum metabolomics reveals the metabolic profile and potential biomarkers of ankylosing spondylitis†","authors":"Liuyan Li, Shuqin Ding, Weibiao Wang, Lingling Yang, Gidion Wilson, Yuping Sa, Yue Zhang, Jianyu Chen and Xueqin Ma","doi":"10.1039/D4MO00076E","DOIUrl":null,"url":null,"abstract":"<p >Ankylosing spondylitis (AS) is a chronic systemic inflammatory disease that significantly impairs physical function in young individuals. However, the identification of radiographic changes in AS is frequently delayed, and the diagnostic efficacy of biomarkers like HLA-B27 remains moderately effective, with unsatisfactory sensitivity and specificity. In contrast to existing literature, our current experiment utilized a larger sample size and employed both untargeted and targeted UHPLC-QTOF-MS/MS based metabolomics to identify the metabolite profile and potential biomarkers of AS. The results indicated a notable divergence between the two groups, and a total of 170 different metabolites were identified, which were associated with the 6 primary metabolic pathways exhibiting a correlation with AS. Among these, 26 metabolites exhibited high sensitivity and specificity with area under curve (AUC) values greater than 0.8. Subsequent targeted quantitative analysis discovered 3 metabolites, namely 3-amino-2-piperidone, hypoxanthine and octadecylamine, exhibiting excellent distinguishing ability based on the results of the ROC curve and the Random Forest model, thus qualifying as potential biomarkers for AS. Summarily, our untargeted and targeted metabolomics investigation offers novel and precise insights into potential biomarkers for AS, potentially enhancing diagnostic capabilities and furthering the comprehension of the condition's pathophysiology.</p>","PeriodicalId":19065,"journal":{"name":"Molecular omics","volume":" 8","pages":" 505-516"},"PeriodicalIF":3.0000,"publicationDate":"2024-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular omics","FirstCategoryId":"99","ListUrlMain":"https://pubs.rsc.org/en/content/articlelanding/2024/mo/d4mo00076e","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Ankylosing spondylitis (AS) is a chronic systemic inflammatory disease that significantly impairs physical function in young individuals. However, the identification of radiographic changes in AS is frequently delayed, and the diagnostic efficacy of biomarkers like HLA-B27 remains moderately effective, with unsatisfactory sensitivity and specificity. In contrast to existing literature, our current experiment utilized a larger sample size and employed both untargeted and targeted UHPLC-QTOF-MS/MS based metabolomics to identify the metabolite profile and potential biomarkers of AS. The results indicated a notable divergence between the two groups, and a total of 170 different metabolites were identified, which were associated with the 6 primary metabolic pathways exhibiting a correlation with AS. Among these, 26 metabolites exhibited high sensitivity and specificity with area under curve (AUC) values greater than 0.8. Subsequent targeted quantitative analysis discovered 3 metabolites, namely 3-amino-2-piperidone, hypoxanthine and octadecylamine, exhibiting excellent distinguishing ability based on the results of the ROC curve and the Random Forest model, thus qualifying as potential biomarkers for AS. Summarily, our untargeted and targeted metabolomics investigation offers novel and precise insights into potential biomarkers for AS, potentially enhancing diagnostic capabilities and furthering the comprehension of the condition's pathophysiology.

Abstract Image

查看原文本刊更多论文

血清代谢组学揭示强直性脊柱炎的代谢特征和潜在生物标记物

强直性脊柱炎（AS）是一种慢性全身性炎症，严重损害年轻人的身体功能。然而，强直性脊柱炎的影像学变化常常被延迟发现，HLA-B27 等生物标志物的诊断效果也一般，灵敏度和特异性都不尽如人意。与现有文献相比，本实验采用了更大的样本量，并同时使用了基于超高效液相色谱-质谱-质谱（UHPLC-QTOF-MS/MS）的非靶向和靶向代谢组学方法来鉴定强直性脊柱炎的代谢物谱和潜在生物标志物。结果表明，两组之间存在明显差异，共有170种不同的代谢物与强直性脊柱炎的6种主要代谢途径相关。其中，26种代谢物具有较高的灵敏度和特异性，曲线下面积（AUC）值均大于0.8。随后的靶向定量分析发现了3个代谢物，即3-氨基-2-哌啶酮、次黄嘌呤和十八胺，根据ROC曲线和随机森林模型的结果，这3个代谢物表现出了极佳的鉴别能力，因此可作为强直性脊柱炎的潜在生物标记物。总之，我们的非靶向和靶向代谢组学研究为了解强直性脊柱炎的潜在生物标志物提供了新颖而精确的见解，从而有可能提高诊断能力并加深对该疾病病理生理学的理解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Molecular omics Biochemistry, Genetics and Molecular Biology-Biochemistry

CiteScore

5.40

自引率

3.40%

发文量

期刊介绍： Molecular Omics publishes high-quality research from across the -omics sciences. Topics include, but are not limited to: -omics studies to gain mechanistic insight into biological processes – for example, determining the mode of action of a drug or the basis of a particular phenotype, such as drought tolerance -omics studies for clinical applications with validation, such as finding biomarkers for diagnostics or potential new drug targets -omics studies looking at the sub-cellular make-up of cells – for example, the subcellular localisation of certain proteins or post-translational modifications or new imaging techniques -studies presenting new methods and tools to support omics studies, including new spectroscopic/chromatographic techniques, chip-based/array technologies and new classification/data analysis techniques. New methods should be proven and demonstrate an advance in the field. Molecular Omics only accepts articles of high importance and interest that provide significant new insight into important chemical or biological problems. This could be fundamental research that significantly increases understanding or research that demonstrates clear functional benefits. Papers reporting new results that could be routinely predicted, do not show a significant improvement over known research, or are of interest only to the specialist in the area are not suitable for publication in Molecular Omics.